Femoral Rami Obturator Nerve Trunk (FRONT) Block in Intramedullary Nail Surgery .
NCT ID: NCT07268911
Last Updated: 2025-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
20 participants
INTERVENTIONAL
2025-11-01
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Block Group
will receive FRONT block
Femoral rami obturator nerve trunk (FRONT) block
ultrasound-guided FRONT block will be performed at the infrainguinal level, targeting the iliopsoas plane. Using the same needle approach, the subpectineal compartment will be also accessed . We will use ultrasound and electrical nerve stimulation guidance (0.4 mA, 0.1 ms, without eliciting a motor response) to avoid direct involvement of the femoral nerve. A total of 40 mL (20 mL for the iliopsoas plane and 20 mL for the subpectineal compartment) of 0.125% plain levobupivacaine will be administered.
Control group
will receive conventional analgesia
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Femoral rami obturator nerve trunk (FRONT) block
ultrasound-guided FRONT block will be performed at the infrainguinal level, targeting the iliopsoas plane. Using the same needle approach, the subpectineal compartment will be also accessed . We will use ultrasound and electrical nerve stimulation guidance (0.4 mA, 0.1 ms, without eliciting a motor response) to avoid direct involvement of the femoral nerve. A total of 40 mL (20 mL for the iliopsoas plane and 20 mL for the subpectineal compartment) of 0.125% plain levobupivacaine will be administered.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* American Society of Anesthesiologists (ASA) classification 1-2
* patients who undergoing surgery for intramedullary nail surgery.
Exclusion Criteria
* patients with a history of mild cognitive impairment (MCI), dementia, and delirium
* patients with known preoperative infections (pulmonary infection, urinary infection, and sepsis).
* coagulopathy
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
South Valley University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohamed Gaber Ahmed
lecturer in anesthesia, Intensive Care and Pain Management
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zeinab M Sayed, MD
Role: STUDY_DIRECTOR
Qena University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Qena University
Qina, Qena Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ِAIP029-4
Identifier Type: -
Identifier Source: org_study_id